Base de dados : MEDLINE
Pesquisa : F01.470.323 [Categoria DeCS]
Referências encontradas : 853 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 86 ir para página                         

  1 / 853 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28285265
[Au] Autor:Murphy R; O'Donoghue S; Counihan T; McDonald C; Calabresi PA; Ahmed MA; Kaplin A; Hallahan B
[Ad] Endereço:Department of Psychiatry, University College Hospital Galway, Galway, Ireland.
[Ti] Título:Neuropsychiatric syndromes of multiple sclerosis.
[So] Source:J Neurol Neurosurg Psychiatry;88(8):697-708, 2017 Aug.
[Is] ISSN:1468-330X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neuropsychiatric signs and symptoms occur frequently in individuals with multiple sclerosis (MS), either as the initial presenting complaint prior to a definitive neurological diagnosis or more commonly with disease progression. However, the pathogenesis of these comorbid conditions remains unclear and it remains difficult to accurately elucidate if neuropsychiatric symptoms or conditions are indicators of MS illness severity. Furthermore, both the disease process and the treatments of MS can adversely impact an individual's mental health. In this review, we discuss the common neuropsychiatric syndromes that occur in MS and describe the clinical symptoms, aetiology, neuroimaging findings and management strategies for these conditions.
[Mh] Termos MeSH primário: Esclerose Múltipla/diagnóstico
Transtornos Neurocognitivos/diagnóstico
[Mh] Termos MeSH secundário: Sintomas Afetivos/diagnóstico
Sintomas Afetivos/fisiopatologia
Sintomas Afetivos/psicologia
Transtornos de Ansiedade/diagnóstico
Transtornos de Ansiedade/fisiopatologia
Transtornos de Ansiedade/psicologia
Transtorno Bipolar/diagnóstico
Transtorno Bipolar/fisiopatologia
Transtorno Bipolar/psicologia
Encéfalo/patologia
Encéfalo/fisiopatologia
Mapeamento Encefálico
Transtorno Depressivo Maior/diagnóstico
Transtorno Depressivo Maior/fisiopatologia
Transtorno Depressivo Maior/psicologia
Euforia/fisiologia
Seres Humanos
Imagem por Ressonância Magnética
Esclerose Múltipla/fisiopatologia
Esclerose Múltipla/psicologia
Transtornos Neurocognitivos/fisiopatologia
Transtornos Neurocognitivos/psicologia
Testes Neuropsicológicos
Transtornos Psicóticos/diagnóstico
Transtornos Psicóticos/fisiopatologia
Transtornos Psicóticos/psicologia
Psicotrópicos
Transtornos Relacionados ao Uso de Substâncias/diagnóstico
Transtornos Relacionados ao Uso de Substâncias/fisiopatologia
Transtornos Relacionados ao Uso de Substâncias/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170313
[St] Status:MEDLINE
[do] DOI:10.1136/jnnp-2016-315367


  2 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27550152
[Au] Autor:Horsfall JT; Sprague JE
[Ad] Endereço:Crystal Clinic Orthopaedic Center, Akron, OH, USA.
[Ti] Título:The Pharmacology and Toxicology of the 'Holy Trinity'.
[So] Source:Basic Clin Pharmacol Toxicol;120(2):115-119, 2017 Feb.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Combining opioids with benzodiazepines and skeletal muscle relaxants ('The Holy Trinity') has been reported to potentiate the 'high'. Through unique interactions with colocalized µ-opioid and GABA receptors, the combined use of these agents induces a synergistic increase in dopamine in the nucleus accumbens (NAc) and depression of respiration. The inhibition of GABA release mediated by µ -opioid receptor activation results in a subsequent increase in dopamine in the NAc. Benzodiazepines activate the GABA R to suppress respiration in the medullary respiratory centres. The skeletal muscle relaxant, carisoprodol, appears to bind to a unique binding domain within the GABA R to further enhance the respiratory depressant effects of the benzodiazepines. Therefore, the opioids, the benzodiazepines and carisoprodol alone or in combination are capable of inducing respiratory depression. Current guidelines for opioid prescribing recommend against the concomitant use of benzodiazepines but do not recognize the potential risk associated with the addition of skeletal muscle relaxants.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Benzodiazepinas/efeitos adversos
Carisoprodol/efeitos adversos
Euforia/efeitos dos fármacos
Moduladores GABAérgicos/efeitos adversos
Fármacos Neuromusculares/efeitos adversos
Núcleo Accumbens/efeitos dos fármacos
Insuficiência Respiratória/induzido quimicamente
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Animais
Benzodiazepinas/administração & dosagem
Carisoprodol/administração & dosagem
Contraindicações
Dopamina/metabolismo
Cálculos da Dosagem de Medicamento
Sinergismo Farmacológico
Quimioterapia Combinada
Moduladores GABAérgicos/administração & dosagem
Seres Humanos
Fármacos Neuromusculares/administração & dosagem
Núcleo Accumbens/metabolismo
Núcleo Accumbens/fisiopatologia
Transtornos Relacionados ao Uso de Opioides/metabolismo
Transtornos Relacionados ao Uso de Opioides/fisiopatologia
Transtornos Relacionados ao Uso de Opioides/psicologia
Guias de Prática Clínica como Assunto
Respiração/efeitos dos fármacos
Insuficiência Respiratória/metabolismo
Insuficiência Respiratória/fisiopatologia
Medição de Risco
Transdução de Sinais/efeitos dos fármacos
Ácido gama-Aminobutírico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (GABA Modulators); 0 (Neuromuscular Agents); 12794-10-4 (Benzodiazepines); 21925K482H (Carisoprodol); 56-12-2 (gamma-Aminobutyric Acid); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12655


  3 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27287796
[Au] Autor:Preuß P; Schulte-Herbrüggen O
[Ad] Endereço:Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin, St. Hedwig-Krankenhaus, Große Hamburger Str. 5-11, 10435 Berlin, Germany, patricia.preuss@charite.de.
[Ti] Título:Euphoria as a Peri-traumatic Emotion in PTSD - How Positively Perceived Emotions Can Affect the Maintenance of the Disorder: a Case Report.
[So] Source:Psychiatr Danub;28(2):193-4, 2016 Jun.
[Is] ISSN:0353-5053
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Mh] Termos MeSH primário: Adultos Sobreviventes de Eventos Adversos na Infância/psicologia
Vítimas de Crime/psicologia
Euforia
Trauma Psicológico/psicologia
Transtornos de Estresse Pós-Traumáticos/psicologia
[Mh] Termos MeSH secundário: Adulto
Emoções
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160611
[Lr] Data última revisão:
160611
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160612
[St] Status:MEDLINE


  4 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27287610
[Au] Autor:Bjarnadottir GD; Magnusson A; Rafnar BO; Sigurdsson E; Steingrimsson S; Johannsson M; Bragadottir H; Haraldsson HM
[Ad] Endereço:Mental Health Services, Landspitali - National University Hospital, Reykjavik, Iceland.
[Ti] Título:Intravenous Use of Prescription Psychostimulants; A Comparison of the Pattern and Subjective Experience between Different Methylphenidate Preparations, Amphetamine and Cocaine.
[So] Source:Eur Addict Res;22(5):259-67, 2016.
[Is] ISSN:1421-9891
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Methylphenidate (MPH) has been the most commonly used intravenous (i.v.) substance in Iceland in recent years. In Iceland, MPH is available in 3 forms: immediate-release (IR) tablets (MPH IR, short-acting), sustainable-release (SR) capsules (MPH SR, long-acting) and osmotic-release (OROS) tablets (MPH OROS, long-acting). The aims of the study were to compare the pattern and subjective effects of i.v. MPH use to other i.v. psychostimulants and examine whether the pattern of use differs among MPH preparations. METHODS: This is a nationwide descriptive study. Information was collected from 95 i.v. substance users undergoing inpatient detoxification and reporting i.v. MPH use in the last 30 days using a semi-structured interview. RESULTS: MPH SR was both the most commonly used (96%) and preferred i.v. psychostimulant (57%). The intensity and duration of 'euphoria' did not differ between cocaine and MPH SR. No participant reported MPH OROS as their preferred substance even though a third had used it in the past month. CONCLUSIONS: The pattern of i.v. MPH use is similar to other psychostimulants among treatment seeking patients. MPH OROS was the least preferred i.v. psychostimulant, despite having the largest market share in Iceland. The results indicate that MPH OROS has less abuse potential than other MPH preparations.
[Mh] Termos MeSH primário: Anfetamina/administração & dosagem
Estimulantes do Sistema Nervoso Central/administração & dosagem
Cocaína/administração & dosagem
Euforia/efeitos dos fármacos
Metilfenidato/administração & dosagem
Uso Indevido de Medicamentos sob Prescrição/psicologia
[Mh] Termos MeSH secundário: Administração Intravenosa
Adulto
Anfetamina/efeitos adversos
Estimulantes do Sistema Nervoso Central/efeitos adversos
Cocaína/efeitos adversos
Estudos Transversais
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/efeitos adversos
Composição de Medicamentos
Feminino
Seres Humanos
Islândia/epidemiologia
Masculino
Metilfenidato/efeitos adversos
Uso Indevido de Medicamentos sob Prescrição/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Delayed-Action Preparations); 207ZZ9QZ49 (Methylphenidate); CK833KGX7E (Amphetamine); I5Y540LHVR (Cocaine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160612
[St] Status:MEDLINE
[do] DOI:10.1159/000446428


  5 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27253658
[Au] Autor:Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
[Ad] Endereço:From the *Altreos Research Partners Inc, Toronto, Ontario, Canada; †Merck & Co., Inc., Kenilworth, NJ; ‡University of Toronto; §DL Global Partners; and ∥INC Research, Toronto, Ontario, Canada.
[Ti] Título:Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
[So] Source:J Clin Psychopharmacol;36(4):314-23, 2016 Aug.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Suvorexant is a dual orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia at a maximum dose of 20 mg. This randomized double-blind crossover study evaluated the abuse potential of suvorexant in 36 healthy recreational polydrug users with a history of sedative and psychedelic drug use. Single doses of suvorexant (40, 80, and 150 mg: 2-7.5 × maximum dose), zolpidem (15 and 30 mg: 1.5-3 × maximum dose), and placebo were administered, with a 10-day washout between treatments. Subjective and objective measures, including visual analog scales (VASs), Addiction Research Center Inventory, and cognitive/psychomotor tests, were evaluated for 24-hour postdose. Suvorexant had significantly greater peak effects on "drug liking" VAS (primary endpoint) than placebo. Although effects of suvorexant on abuse potential measures were generally similar to zolpidem, they remained constant across doses, whereas zolpidem often had greater effects at higher doses. Suvorexant (all doses) had significantly fewer effects than zolpidem 30 mg on secondary measures, such as "high" VAS, Bowdle VAS, and Addiction Research Center Inventory morphine-benzedrine group. The overall incidence of abuse-related adverse events, such as euphoric mood and hallucination, was numerically lower with suvorexant than zolpidem. In agreement with its classification as a schedule IV drug, suvorexant demonstrated abuse potential, compared with placebo. The abuse potential was similar to zolpidem using certain measures, but with a reduced incidence of abuse-related adverse events. Although this suggests that the overall abuse liability of suvorexant may be lower than zolpidem, the actual abuse rates will be assessed with the postmarketing experience.
[Mh] Termos MeSH primário: Azepinas/farmacologia
Euforia/efeitos dos fármacos
Alucinações/induzido quimicamente
Hipnóticos e Sedativos/farmacologia
Antagonistas dos Receptores de Orexina/farmacologia
Piridinas/farmacologia
Triazóis/farmacologia
[Mh] Termos MeSH secundário: Adulto
Azepinas/administração & dosagem
Azepinas/efeitos adversos
Estudos Cross-Over
Método Duplo-Cego
Feminino
Seres Humanos
Hipnóticos e Sedativos/administração & dosagem
Hipnóticos e Sedativos/efeitos adversos
Masculino
Meia-Idade
Antagonistas dos Receptores de Orexina/administração & dosagem
Antagonistas dos Receptores de Orexina/efeitos adversos
Uso Indevido de Medicamentos sob Prescrição
Piridinas/administração & dosagem
Piridinas/efeitos adversos
Drogas Ilícitas
Triazóis/administração & dosagem
Triazóis/efeitos adversos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Azepines); 0 (Hypnotics and Sedatives); 0 (Orexin Receptor Antagonists); 0 (Pyridines); 0 (Street Drugs); 0 (Triazoles); 081L192FO9 (suvorexant); 7K383OQI23 (zolpidem)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160603
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000516


  6 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26767525
[Au] Autor:Schjerning O; Rosenzweig M; Pottegård A; Damkier P; Nielsen J
[Ad] Endereço:Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark. o.schjerning@rn.dk.
[Ti] Título:Abuse Potential of Pregabalin: A Systematic Review.
[So] Source:CNS Drugs;30(1):9-25, 2016 Jan.
[Is] ISSN:1179-1934
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known. OBJECTIVE: The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin. METHODS: We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin. RESULTS: We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers. CONCLUSIONS: Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.
[Mh] Termos MeSH primário: Pregabalina/efeitos adversos
Uso Indevido de Medicamentos sob Prescrição
Drogas Ilícitas/efeitos adversos
Transtornos Relacionados ao Uso de Substâncias
[Mh] Termos MeSH secundário: Animais
Ensaios Clínicos como Assunto
Avaliação Pré-Clínica de Medicamentos
Euforia/efeitos dos fármacos
Seres Humanos
Uso Indevido de Medicamentos sob Prescrição/estatística & dados numéricos
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Street Drugs); 55JG375S6M (Pregabalin)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160116
[St] Status:MEDLINE
[do] DOI:10.1007/s40263-015-0303-6


  7 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26748678
[Au] Autor:Van Meter AR; Burke C; Kowatch RA; Findling RL; Youngstrom EA
[Ad] Endereço:Ferkauf Graduate School of Psychology, Yeshiva University, Albert Einstein College of Medicine, Bronx, NY, USA.
[Ti] Título:Ten-year updated meta-analysis of the clinical characteristics of pediatric mania and hypomania.
[So] Source:Bipolar Disord;18(1):19-32, 2016 Feb.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The phenomenology and diagnosis of pediatric bipolar disorder has been controversial. We aimed to update a 2005 meta analysis of the prevalence of manic symptoms in youth, in order to determine whether the picture of pediatric mania has changed as research on pediatric bipolar disorder has grown. METHODS: We conducted literature reviews in PsycINFO and PubMed; studies with the prevalence of manic symptoms in youth were included. Two raters coded each study; kappa was 0.86-1.0. RESULTS: Twenty studies were meta-analyzed (N = 2,226 youths). The most common symptoms across bipolar subtypes, using a random-effects model, were: increased energy 79%, irritability 77%, mood lability 76%, distractibility 74%, goal-directed activity 72%, euphoric/elated mood 64%, pressured speech 63%, hyperactive 62%, racing thoughts 61%, poor judgment 61%, grandiosity 57%, inappropriate laughter 57%, decreased need for sleep 56%, and flight of ideas 54%. Symptom rates were heterogeneous across samples; potential predictors were explored but no clear patterns were found. CONCLUSIONS: Debate continues about the definitions of pediatric bipolar disorder; the results of this meta-analysis suggest that there is significant heterogeneity of symptom prevalence between studies, and that symptoms vary widely across individuals. Understanding the roots of this heterogeneity could broaden understanding of the complex clinical presentation of pediatric mania, and aid in diagnosis.
[Mh] Termos MeSH primário: Transtorno Bipolar/psicologia
Transtorno Ciclotímico/psicologia
Euforia
Humor Irritável
Riso
[Mh] Termos MeSH secundário: Adolescente
Criança
Seres Humanos
Prevalência
Escalas de Graduação Psiquiátrica
Transtornos do Sono-Vigília/psicologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160216
[Lr] Data última revisão:
160216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160111
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12358


  8 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26670786
[Au] Autor:Erickson JM; Quinn DK; Shorter E
[Ad] Endereço:From the Division of Consultation Liaison Psychiatry & Psychosomatic Medicine, Icahn School of Medicine, Mount Sinai Beth Israel, New York (JME); Psychiatric Consultation Service, University of New Mexico School of Medicine, Albuquerque (DKQ); and Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (ES).
[Ti] Título:Moria Revisited: Translation of Moritz Jastrowitz's Description of Pathologic Giddiness.
[So] Source:J Neuropsychiatry Clin Neurosci;28(2):74-6, 2016.
[Is] ISSN:1545-7222
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Encefalopatias/patologia
Euforia
Lobo Frontal/patologia
[Mh] Termos MeSH secundário: Encefalopatias/psicologia
Seres Humanos
Traduções
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170107
[Lr] Data última revisão:
170107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151217
[St] Status:MEDLINE
[do] DOI:10.1176/appi.neuropsych.15080205


  9 / 853 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26547313
[Au] Autor:Carlson JM; Cha J; Fekete T; Greenberg T; Mujica-Parodi LR
[Ad] Endereço:Department of Psychology, Northern Michigan University, 1401 Presque Isle Avenue, Marquette, MI, 49855, USA. joshcarl@nmu.edu.
[Ti] Título:Left medial orbitofrontal cortex volume correlates with skydive-elicited euphoric experience.
[So] Source:Brain Struct Funct;221(8):4269-4279, 2016 Nov.
[Is] ISSN:1863-2661
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The medial orbitofrontal cortex has been linked to the experience of positive affect. Greater medial orbitofrontal cortex volume is associated with greater expression of positive affect and reduced medial orbital frontal cortex volume is associated with blunted positive affect. However, little is known about the experience of euphoria, or extreme joy, and how this state may relate to variability in medial orbitofrontal cortex structure. To test the hypothesis that variability in euphoric experience correlates with the volume of the medial orbitofrontal cortex, we measured individuals' (N = 31) level of self-reported euphoria in response to a highly anticipated first time skydive and measured orbitofrontal cortical volumes with structural magnetic resonance imaging. Skydiving elicited a large increase in self-reported euphoria. Participants' euphoric experience was predicted by the volume of their left medial orbitofrontal cortex such that, the greater the volume, the greater the euphoria. Further analyses indicated that the left medial orbitofrontal cortex and amygdalo-hippocampal complex independently explain variability in euphoric experience and that medial orbitofrontal cortex volume, in conjunction with other structures within the mOFC-centered corticolimbic circuit, can be used to predict individuals' euphoric experience.
[Mh] Termos MeSH primário: Euforia/fisiologia
Córtex Pré-Frontal/anatomia & histologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Tonsila do Cerebelo/anatomia & histologia
Tonsila do Cerebelo/fisiologia
Feminino
Hipocampo/anatomia & histologia
Hipocampo/fisiologia
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Córtex Pré-Frontal/fisiologia
Máquina de Vetores de Suporte
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151109
[St] Status:MEDLINE


  10 / 853 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26540080
[Au] Autor:Zhao QF; Tan L; Wang HF; Jiang T; Tan MS; Tan L; Xu W; Li JQ; Wang J; Lai TJ; Yu JT
[Ad] Endereço:Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.
[Ti] Título:The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis.
[So] Source:J Affect Disord;190:264-271, 2016 Jan 15.
[Is] ISSN:1573-2517
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Neuropsychiatric symptoms (NPS) are being increasingly recognized as common serious problems in Alzheimer's disease (AD). However, published data on the prevalence of NPS in persons with AD are conflicting. This meta-analysis aimed to estimate the prevalence of NPS in persons with AD. METHODS: Studies published from 1964 to September 30, 2014, were identified from PubMed and Embase database, reference lists and conference abstracts. We calculated prevalence rates and conducted meta-regression analysis with random-effects model, according to study characteristics, population demographics or condition information. RESULTS: We identified 48 eligible articles, which provided data for 12 NPS reported in Neuropsychiatric Inventory (NPI). The most frequent NPS was apathy, with an overall prevalence of 49% (95% CI 41-57%), followed by depression, aggression, anxiety and sleep disorder, the pooled prevalence estimates of which were 42% (95% CI 37-46%), 40% (95% CI 33-46%), 39% (95% CI 32-46%) and 39% (95% CI 30-47%), respectively. The less prevalent NPS were irritability (36%, 31-41%), appetite disorder (34%, 27-41%), aberrant motor behavior (32%, 25-38%), delusion (31%, 27-35%), disinhibition (17%, 12-21%) and hallucination (16%, 13-18%). Least common was euphoria, with an overall prevalence of 7% (95% CI 5-9%). LIMITATIONS: Several aspects, such as the quality of included studies were not always optimal and there was significant heterogeneity of prevalence estimate across studies. CONCLUSIONS: NPS were observed to be highly prevalent in AD patients. Disease duration, age, education level, population origin and the severity of cognitive impairment had influence on the prevalence of some NPS.
[Mh] Termos MeSH primário: Doença de Alzheimer/epidemiologia
Doença de Alzheimer/psicologia
Ansiedade/epidemiologia
Delusões/epidemiologia
Depressão/epidemiologia
Transtornos da Alimentação e da Ingestão de Alimentos/epidemiologia
Alucinações/epidemiologia
Transtornos do Sono-Vigília/epidemiologia
[Mh] Termos MeSH secundário: Agressão
Apatia
Comorbidade
Euforia
Seres Humanos
Humor Irritável
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151106
[St] Status:MEDLINE



página 1 de 86 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde